Frontier Capital Management’s Climb Bio CLYM Stock Holding History
Bought
Maintained
Sold
Other funds holding CLYM
Frontier Capital Management's CLYM Position: Q3 2026 in Review
Frontier Capital Management increased its Climb Bio (CLYM) stake by 7.9% in Q3 2026, buying an estimated $2.14M and bringing the position to 2,092,424 shares worth $24M. The position accounts for 0.26% of the portfolio, ranked #145.
Frontier Capital Management first reported a position in CLYM in Q2 2026 and has held it in 2 quarters since. The position peaked at $25.3M in Q2 2026. 127 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.
- Frontier Capital Management held 2,092,424 shares of Climb Bio worth $24M as of Q3 2026.
- Frontier Capital Management bought 153,405 Climb Bio shares in Q3 2026, an estimated $2.14M.
- Climb Bio made up 0.26% of Frontier Capital Management's portfolio in Q3 2026, its #145 holding.
- Frontier Capital Management first reported a position in Climb Bio in Q2 2026 and has held it in 2 quarters since.
- Frontier Capital Management's Climb Bio position peaked at $25.3M in Q2 2026.
- 127 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.
Based on Frontier Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.